Your browser doesn't support javascript.
loading
Changes in diabetes prescription patterns following Affordable Care Act Medicaid expansion.
Gemelas, Jordan; Marino, Miguel; Valenzuela, Steele; Schmidt, Teresa; Suchocki, Andrew; Huguet, Nathalie.
Afiliação
  • Gemelas J; Department of Family Medicine, Oregon Health & Science University, Portland, Oregon, USA gemelas@ohsu.edu.
  • Marino M; School of Public Health, Oregon Health & Science University - Portland State University, Portland, Oregon, USA.
  • Valenzuela S; Department of Family Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Schmidt T; Department of Biostatistics, Oregon Health & Science University - Portland State University, Portland, Oregon, USA.
  • Suchocki A; Department of Family Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Huguet N; Research Department, OCHIN, Portland, Oregon, USA.
BMJ Open Diabetes Res Care ; 9(Suppl 1)2021 12.
Article em En | MEDLINE | ID: mdl-34933870
INTRODUCTION: Most patients with diabetes mellitus are prescribed medications to control their blood glucose. The implementation of the Affordable Care Act (ACA) led to improved access to healthcare for patients with diabetes. However, impact of the ACA on prescribing trends by diabetes drug category is less clear. This study aims to assess if long-acting insulin and novel agents were prescribed more frequently following the ACA in states that expanded Medicaid compared with non-expansion states. RESEARCH DESIGN AND METHODS: In this analysis of a natural experiment, prescriptions reimbursed by Medicaid (US public insurance) for long-acting insulins, metformin, and novel agent medications (DPP4 inhibitors, sodium/glucose cotransporter 2 inhibitor antagonists, and glucagon-like peptide-1 receptor agonists) from 2012 to 2017 were obtained from public records. For each medication category, we performed difference-in-differences (DID) analysis modeling change in rate level from pre-ACA to post-ACA in Medicaid expansion states relative to Medicaid non-expansion states. RESULTS: Expansion and non-expansion states saw a decline in both metformin and long-acting insulin prescriptions per 100 enrollees from pre-ACA to post-ACA. These decreases were larger in non-expansion states relative to expansion states (metformin: absolute DID = +0.33, 95% CI=0.323 to 0.344) and long-acting insulin (absolute DID: +0.11; 95% CI=0.098 to 0.113). Novel agent prescriptions in expansion states (+0.08 per 100 enrollees) saw a higher absolute increase per 100 Medicaid enrollees than in non-expansion states (absolute DID= +0.08, 95% CI=0.079 to 0.086). CONCLUSIONS: There was a greater absolute increase for prescriptions of novel agents in expansion states relative to non-expansion states after accounting for number of enrollees. Reducing administrative barriers and improving the ability of providers to prescribe such newer therapies will be critical for caring for patients with diabetes-particularly in Medicaid non-expansion states.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus / Patient Protection and Affordable Care Act Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: BMJ Open Diabetes Res Care Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus / Patient Protection and Affordable Care Act Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: BMJ Open Diabetes Res Care Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido